Padmanabh P. Bhatt Sells 700 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $38.37 on Friday. The stock has a 50 day simple moving average of $37.14 and a 200 day simple moving average of $34.45. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $39.88. The firm has a market capitalization of $2.12 billion, a PE ratio of 35.86 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the prior year, the company earned ($0.29) earnings per share. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on SUPN. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cantor Fitzgerald started coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an “overweight” rating and a $57.00 price target on the stock. Finally, Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in shares of Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth approximately $72,000. Venturi Wealth Management LLC bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $92,000. Finally, KBC Group NV raised its holdings in shares of Supernus Pharmaceuticals by 53.1% in the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 929 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.